Abstract

To the Editor: Male androgenic alopecia (MAA) is the most common hair loss disorder characterized by miniaturization of hair follicles and progressive hair loss. Although oral drugs, topical agents, and laser therapy can promote hair growth, minoxidil is the only topical therapy approved by the United States Food and Drug Administration. Fibroblast growth factors (FGFs) have a wide range of biological functions. The basic FGF (bFGF) promotes the growthof thehair follicle inmice, indicating its potential as a therapeutic agent for MAA. The nano-microneedle is a new device that can promote transdermal absorption of topical drugs, and increasedrugpenetrationbyup to10or 20 times. In this study, we compared the safety and efficacy of topical minoxidil, nano-microneedle-assisted FGF, and a combination of the two.